The Schall Law Firm Files Class Action Lawsuit Against Kyverna Therapeutics, Inc. for Securities Violations
LOS ANGELES, CA / ACCESS Newswire / February 6, 2025
The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics, Inc. (“Kyverna” or “the Company”) (NASDAQ:KYTX) for violations of the federal securities laws. Investors who purchased the Company’s securities pursuant and/or traceable to the Company’s offering documents issued in connection with its initial public offering (“IPO”) conducted on February 8, 2024, are encouraged to contact the firm before February 7, 2025.
The lawsuit alleges that Kyverna misled investors by making false and misleading statements and failing to disclose material adverse facts about the Company’s business, operations, and prospects. The Company’s stock price has plummeted since the IPO, causing significant financial harm to investors who purchased the securities.
Investors who suffered losses as a result of investing in Kyverna Therapeutics, Inc. may be eligible to participate in the class action lawsuit to recover their losses. The Schall Law Firm is dedicated to protecting shareholder rights and is committed to holding companies accountable for their actions.
If you are a shareholder of Kyverna Therapeutics, Inc. and would like more information about the class action lawsuit or how to participate, please contact The Schall Law Firm before the deadline on February 7, 2025.
How Will This Affect Me?
If you are an investor who purchased securities of Kyverna Therapeutics, Inc. during the IPO conducted on February 8, 2024, you may be eligible to participate in the class action lawsuit to seek recovery of your losses. It is important to act promptly and contact The Schall Law Firm before the deadline on February 7, 2025, to discuss your legal options.
How Will This Affect the World?
The class action lawsuit against Kyverna Therapeutics, Inc. for securities violations serves as a reminder of the importance of transparency and accountability in the financial markets. This legal action aims to hold the Company responsible for its alleged misconduct and to protect the rights of investors who have suffered financial losses as a result of the alleged securities violations.
Conclusion
The filing of the class action lawsuit against Kyverna Therapeutics, Inc. by The Schall Law Firm highlights the firm’s commitment to protecting shareholder rights and seeking justice for investors who have been harmed by alleged securities violations. If you are a shareholder of Kyverna Therapeutics, Inc. and believe you may have a claim, it is important to contact the firm before the deadline to explore your legal options. Transparency and accountability are essential in maintaining the integrity of the financial markets and ensuring investor confidence.
